Introduction {#section1-1559325820942065}
============

Pancreatic cancer is a lethal disease and is characterized as one of the most malignant tumors.^[@bibr1-1559325820942065]^ As estimated by the GLOBOCAN 2018 study,^[@bibr2-1559325820942065]^ 458 918 cases would be diagnosed with pancreatic cancer, and 432 242 cases will die of the disease worldwide in 2018. The global mortality rate coincides with the incidence rate of pancreatic cancer, which emphasizes poor prognosis.^[@bibr3-1559325820942065]^ Pancreatic cancer is usually diagnosed at an advanced stage and the median overall survival (OS) is \<12 months, and the 5-year OS rate is approximately 5%.^[@bibr4-1559325820942065]^ Therapeutic strategies for pancreatic cancer include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. These treatment methods have improved outcomes during the past years.^[@bibr5-1559325820942065]^ However, patients with pancreatic cancer could also develop chemoresistance because of a lack of efficient predictive and prognostic markers.^[@bibr3-1559325820942065],[@bibr6-1559325820942065],[@bibr7-1559325820942065]^ Therefore, to improve the survival of patients with pancreatic cancer, it is important to identify novel and available prognostic biomarkers.

Recently, growing evidence has shown that tumor-elicited inflammation, immune cells, and inflammatory cytokines play critical roles in pancreatic cancer development, progression, and metastasis.^[@bibr8-1559325820942065],[@bibr9-1559325820942065]^ An increasing number of studies have focused on the prognostic role of inflammatory parameters in various cancers.^[@bibr10-1559325820942065]^ These indicators include the neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, systematic inflammatory index, and the modified Glasgow prognostic score (mGPS). The mGPS is based on serum albumin (Alb) and C-reactive protein (CRP) and is scored as mGPS 0, 1, and 2.^[@bibr11-1559325820942065]^ Previous studies have validated the prognostic value of mGPS in various solid tumors, including small cell lung cancer,^[@bibr12-1559325820942065]^ biliary tract cancer,^[@bibr13-1559325820942065]^ renal cell carcinoma (RCC),^[@bibr11-1559325820942065]^ and soft-tissue sarcoma.^[@bibr14-1559325820942065]^ A variety of studies have also investigated the prognostic significance of mGPS in patients with pancreatic cancer; however, the results were inconsistent.^[@bibr15-1559325820942065][@bibr16-1559325820942065][@bibr17-1559325820942065][@bibr18-1559325820942065][@bibr19-1559325820942065][@bibr20-1559325820942065][@bibr21-1559325820942065][@bibr22-1559325820942065][@bibr23-1559325820942065][@bibr24-1559325820942065][@bibr25-1559325820942065][@bibr26-1559325820942065][@bibr27-1559325820942065][@bibr28-1559325820942065][@bibr29-1559325820942065][@bibr30-1559325820942065][@bibr31-1559325820942065][@bibr32-1559325820942065][@bibr33-1559325820942065][@bibr34-1559325820942065][@bibr35-1559325820942065][@bibr36-1559325820942065][@bibr37-1559325820942065][@bibr38-1559325820942065][@bibr39-1559325820942065]-[@bibr40-1559325820942065]^ Therefore, we carried out a meta-analysis to assess the association between mGPS and survival outcomes in patients with pancreatic cancer.

Materials and Methods {#section2-1559325820942065}
=====================

Literature Search Strategy {#section3-1559325820942065}
--------------------------

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline.^[@bibr41-1559325820942065]^ A literature search was performed using PubMed, Web of Science, Embase, and the Cochrane Library. The search terms were as follows: "modified Glasgow prognostic score," "mGPS," "pancreatic neoplasm," "pancreatic cancer," and "pancreatic carcinoma." Only literature published in English was considered. The search was updated on May 10, 2020. The reference lists of selected studies were checked to identify potential inclusions. All related data were extracted from previously published studies; therefore, no ethical approval or informed consent was necessary for this meta-analysis.

Inclusion and Exclusion Criteria {#section4-1559325820942065}
--------------------------------

The inclusion criteria were as follows: (1) diagnosis of pancreatic cancer pathologically or histologically confirmed; (2) CRP and Alb measured from peripheral blood samples before treatment; (3) mGPS scored as the following method: patients with Alb ≥ 3.5 g/dL and CRP ≤ 1 mg/dL are defined as mGPS 0, patients with Alb ≥ 3.5 g/dL and CRP \> 1 mg/dL or Alb \< 3.5 g/dL and CRP ≤ 1 mg/dL are defined as mGPS 1, and patients with Alb \< 3.5 g/dL and CRP \> 1 mg/dL are defined as mGPS 2; (4) the hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) of survival outcomes including OS, progression-free survival (PFS), disease-free survival (DFS), and cancer-specific survival (CSS) supplied in studies or sufficient data were provided; (5) full-text articles published in English. The exclusion criteria were as follows: (1) case reports, reviews, letters, or comments; (2) studies with insufficient information for meta-analysis; (3) overlapping studies; and (4) animal studies.

Data Extraction and Quality Assessment {#section5-1559325820942065}
--------------------------------------

Two independent investigators (W.F. and R.W.) reviewed eligible studies and extracted data. Any disagreements were resolved by discussion with a third reviewer (T.W.) until consensus was reached. The following information was extracted: name of the first author; year of publication; country; sample size; study period; ethnicity; sex; treatment; follow-up; number of patients with mGPS 0, 1, and 2; and survival outcomes. The HRs and 95%CIs were calculated based on mGPS 1 to 2 versus mGPS 0. For studies that reported HRs for mGPS 1 and 2 separately, we combined these 2 groups into a single group and calculated a combined HR to analyze the prognostic role of the overall elevated GPS as previously reported.^[@bibr42-1559325820942065],[@bibr43-1559325820942065]^ Overall survival was the primary outcome of interest. Progression-free survival, DFS, and CSS were secondary outcomes. The methodological qualities of the included studies were assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS)^[@bibr44-1559325820942065]^ by 2 independent investigators (K.W. and S.Y.). The total NOS scores are in the range of 0 to 9. Studies with NOS scores ≥6 were regarded as of high quality.

Statistical Analysis {#section6-1559325820942065}
--------------------

The HRs and 95% CIs were used to estimate the associations between mGPS score and survival outcomes. Heterogeneity among studies was evaluated using Cochran *Q* test and Higgins *I* ^2^ statistic. When the *Q* test (*P* \< .10) or the *I* ^2^ test (\>50%) indicated significant heterogeneity, a random-effect model would be used to combine the data. Otherwise, a fixed-effect model was applied. Subgroup analysis was performed to detect the source and for further investigation. Sensitivity analysis was carried out to evaluate the robustness of the data by omitting one study at a time. Publication bias was examined using Begg rank correlation test. All analyses were performed using Stata version 12.0 software (STATA Corp). Value of *P* \< .05 was considered statistically significant.

Results {#section7-1559325820942065}
=======

Search Results {#section8-1559325820942065}
--------------

The initial literature search retrieved 205 studies in total ([Figure 1](#fig1-1559325820942065){ref-type="fig"}). Of these studies, 151 duplicate records were excluded, and 54 studies were screened by titles and abstracts. Then, 19 articles were removed after title and abstract examination, and 35 studies remained for full-text evaluation. After carefully reviewing the full text, 9 articles were excluded for the following reasons: 7 studies without sufficient data for this meta-analysis, 1 study enrolled overlapping patients, and 1 study did not measure pretreatment mGPS. Finally, 26 studies were included in this meta-analysis.^[@bibr15-1559325820942065][@bibr16-1559325820942065][@bibr17-1559325820942065][@bibr18-1559325820942065][@bibr19-1559325820942065][@bibr20-1559325820942065][@bibr21-1559325820942065][@bibr22-1559325820942065][@bibr23-1559325820942065][@bibr24-1559325820942065][@bibr25-1559325820942065][@bibr26-1559325820942065][@bibr27-1559325820942065][@bibr28-1559325820942065][@bibr29-1559325820942065][@bibr30-1559325820942065][@bibr31-1559325820942065][@bibr32-1559325820942065][@bibr33-1559325820942065][@bibr34-1559325820942065][@bibr35-1559325820942065][@bibr36-1559325820942065][@bibr37-1559325820942065][@bibr38-1559325820942065][@bibr39-1559325820942065]-[@bibr40-1559325820942065]^ The literature selection process is shown in [Figure 1](#fig1-1559325820942065){ref-type="fig"}. In the included studies, one study^[@bibr18-1559325820942065]^ recruited 2 independent cohorts of patients receiving chemotherapy or surgical resection, and the HRs and 95% CIs were separately given for these 2 cohorts. These 2 cohorts were independently analyzed and labeled as Stotz(A) and Stotz(B). Therefore, 27 cohorts from 26 studies were included in this meta-analysis.

![Flowchart of the study selection procedure in the meta-analysis.](10.1177_1559325820942065-fig1){#fig1-1559325820942065}

Characteristics of the Included Studies {#section9-1559325820942065}
---------------------------------------

The included studies were published from 2012 to 2019, with a total of 5198 cases. The sample sizes ranged from 25 to 807, with a median value of 172. The included studies were conducted in 8 countries, including Japan (n = 16),^[@bibr20-1559325820942065][@bibr21-1559325820942065]-[@bibr22-1559325820942065],[@bibr24-1559325820942065],[@bibr25-1559325820942065],[@bibr27-1559325820942065],[@bibr29-1559325820942065][@bibr30-1559325820942065][@bibr31-1559325820942065]-[@bibr32-1559325820942065],[@bibr35-1559325820942065][@bibr36-1559325820942065][@bibr37-1559325820942065][@bibr38-1559325820942065][@bibr39-1559325820942065]-[@bibr40-1559325820942065]^ China (n = 4),^[@bibr17-1559325820942065],[@bibr23-1559325820942065],[@bibr26-1559325820942065],[@bibr28-1559325820942065]^ Austria (n = 2 cohorts),^[@bibr18-1559325820942065]^ Australia (n = 1),^[@bibr19-1559325820942065]^ the United Kingdom (n = 1),^[@bibr15-1559325820942065]^ Greece (n = 1),^[@bibr33-1559325820942065]^ Italy (n = 1),^[@bibr16-1559325820942065]^ and Korea (n = 1).^[@bibr34-1559325820942065]^ A total of 24 studies with 4651 patients^[@bibr15-1559325820942065][@bibr16-1559325820942065]-[@bibr17-1559325820942065],[@bibr19-1559325820942065][@bibr20-1559325820942065][@bibr21-1559325820942065][@bibr22-1559325820942065][@bibr23-1559325820942065][@bibr24-1559325820942065][@bibr25-1559325820942065][@bibr26-1559325820942065][@bibr27-1559325820942065][@bibr28-1559325820942065][@bibr29-1559325820942065][@bibr30-1559325820942065][@bibr31-1559325820942065][@bibr32-1559325820942065][@bibr33-1559325820942065]-[@bibr34-1559325820942065],[@bibr36-1559325820942065][@bibr37-1559325820942065][@bibr38-1559325820942065][@bibr39-1559325820942065]-[@bibr40-1559325820942065]^ provided data on the correlation between mGPS and OS. Seven cohorts presented the data on the prognostic value of mGPS for PFS, DFS, and CSS, including 3 for PFS,^[@bibr29-1559325820942065],[@bibr30-1559325820942065],[@bibr38-1559325820942065]^ 2 for DFS,^[@bibr31-1559325820942065],[@bibr35-1559325820942065]^ and 2 for CSS.^[@bibr18-1559325820942065]^ The major characteristics of the enrolled studies are summarized in [Table 1](#table1-1559325820942065){ref-type="table"}. The NOS scores ranged from 6 to 8, and the median value was 7, which suggested that all eligible studies were of high quality.

###### 

Characteristics of Studies Included in the Present Meta-Analysis.

![](10.1177_1559325820942065-table1)

  Author                                  Year   Country              Sample size   Study duration   Ethnicity   Sex (M/F)   TNM stage   Treatment            Follow-up median (months)   mGPS (0/1/2)   Outcomes   NOS score
  --------------------------------------- ------ -------------------- ------------- ---------------- ----------- ----------- ----------- -------------------- --------------------------- -------------- ---------- -----------
  Jamieson^[@bibr15-1559325820942065]^    2012   The United Kingdom   173           1997-2009        Caucasian   93/80       I-III       Surgical resection   27                          95/37/41       OS         8
  La Torre^[@bibr16-1559325820942065]^    2012   Italy                101           2003-2009        Caucasian   53/48       I-IV        Surgical resection   19                          37/20/25       OS         7
  Wang^[@bibr17-1559325820942065]^        2012   China                177           2006-2010        Asian       120/57      I-IV        Mixed                31.33                       115/46/16      OS         7
  Stotz(A)^[@bibr18-1559325820942065]^    2013   Austria              261           2004-2010        Caucasian   103/158     III-IV      Chemotherapy         5                           117/115/29     CSS        7
  Stotz(B)^[@bibr18-1559325820942065]^    2013   Austria              110           2004-2010        Caucasian   51/59       I-III       Surgical resection   18                          73/21/16       CSS        8
  Martin^[@bibr19-1559325820942065]^      2014   Australia            124           2008-2012        Caucasian   66/58       III-IV      Chemotherapy         12                          46/26/52       OS         7
  Inoue^[@bibr20-1559325820942065]^       2015   Japan                440           2008-2012        Asian       249/191     I-IV        Mixed                18.7                        367/49/24      OS         7
  Kasuga^[@bibr21-1559325820942065]^      2015   Japan                61            2009-2013        Asian       40/21       IV          Chemotherapy         6.3                         NA             OS         6
  Imaoka^[@bibr22-1559325820942065]^      2016   Japan                807           2001-2013        Asian       473/334     I-IV        Mixed                15.8                        620/153/34     OS         7
  Wu^[@bibr23-1559325820942065]^          2016   China                233           2011-2014        Asian       156/77      III-IV      Chemotherapy         4.4                         NA             OS         6
  Yamada^[@bibr24-1559325820942065]^      2016   Japan                379           2002-2014        Asian       228/151     I-IV        Surgical resection   15.1                        189/80/36      OS         7
  Iino^[@bibr25-1559325820942065]^        2017   Japan                47            2010-2015        Asian       24/23       III-IV      Chemotherapy         NA                          35/5/7         OS         6
  Liu^[@bibr26-1559325820942065]^         2017   China                386           2010-2015        Asian       238/148     I-IV        Mixed                8.7                         121/242/13     OS         8
  Matsumoto^[@bibr27-1559325820942065]^   2017   Japan                25            2007-2013        Asian       14/11       I-IV        Surgical resection   36.3                        20/2/3         OS         8
  Xiao^[@bibr28-1559325820942065]^        2017   China                66            2012-2013        Asian       30/36       III-IV      Chemotherapy         NA                          39/11/16       OS         6
  Abe^[@bibr29-1559325820942065]^         2018   Japan                329           1996-2014        Asian       198/131     I-III       Surgical resection   NA                          282/27/20      OS, PFS    6
  Asama^[@bibr30-1559325820942065]^       2018   Japan                72            2006-2016        Asian       40/32       III-IV      Chemotherapy         8                           52/11/9        OS, PFS    8
  Fujiwara^[@bibr31-1559325820942065]^    2018   Japan                188           2000-2015        Asian       115/73      I-IV        Surgical resection   28.9                        140/21/27      OS, DFS    7
  Ikuta^[@bibr32-1559325820942065]^       2018   Japan                38            2011-2018        Asian       20/18       III-IV      Chemotherapy         39.8                        30/7/1         OS         7
  Christos^[@bibr33-1559325820942065]^    2019   Greece               226           2004-2015        Caucasian   124/102     I-IV        Surgical resection   23.1                        NA             OS         6
  Hwang^[@bibr34-1559325820942065]^       2019   Korea                203           Jan-Dec 2016     Asian       116/87      IV          Chemotherapy         21.5                        137/19/47      OS         8
  Ichikawa^[@bibr35-1559325820942065]^    2019   Japan                176           2005-2015        Asian       116/60      III-IV      Chemotherapy         To Dec 2017                 157/13/6       DFS        8
  Ikuta^[@bibr36-1559325820942065]^       2019   Japan                136           2005-2017        Asian       76/60       I-IV        Surgical resection   16.8                        NA             OS         6
  Kubo^[@bibr37-1559325820942065]^        2019   Japan                119           2009-2017        Asian       66/53       I-III       Chemoradiotherapy    NA                          NA             OS         6
  Matsumoto^[@bibr38-1559325820942065]^   2019   Japan                66            2013-2014        Asian       44/22       IV          Chemotherapy         12.7 (1.8-21.1)             NA             OS, PFS    6
  Nakagawa^[@bibr39-1559325820942065]^    2019   Japan                172           2006-2015        Asian       102/70      I-III       Surgical resection   To December 2017            NA             OS         7
  Shimizu^[@bibr40-1559325820942065]^     2019   Japan                83            2008-2014        Asian       57/26       IV          Chemotherapy         NA                          44/28/11       OS         6

Abbreviations: CSS, cancer-specific survival; DFS, disease-free survival; F, female; M, male; mGPS, modified Glasgow Prognostic Score; NA, not available; NOS, Newcastle Ottawa Scale; OS, overall survival; PFS, progression-free survival.

Association Between mGPS and OS {#section10-1559325820942065}
-------------------------------

A total of 24 cohort studies consisting of 4651 patients^[@bibr15-1559325820942065][@bibr16-1559325820942065]-[@bibr17-1559325820942065],[@bibr19-1559325820942065][@bibr20-1559325820942065][@bibr21-1559325820942065][@bibr22-1559325820942065][@bibr23-1559325820942065][@bibr24-1559325820942065][@bibr25-1559325820942065][@bibr26-1559325820942065][@bibr27-1559325820942065][@bibr28-1559325820942065][@bibr29-1559325820942065][@bibr30-1559325820942065][@bibr31-1559325820942065][@bibr32-1559325820942065][@bibr33-1559325820942065]-[@bibr34-1559325820942065],[@bibr36-1559325820942065][@bibr37-1559325820942065][@bibr38-1559325820942065][@bibr39-1559325820942065]-[@bibr40-1559325820942065]^ reported the HRs and 95% CIs for the relationship between mGPS and OS in pancreatic cancer. A random-effects model was applied due to significant heterogeneity (*I* ^2^ = 68.1%, *P* \< .001, [Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 2A](#fig2-1559325820942065){ref-type="fig"}). The pooled data demonstrated that pretreatment mGPS was significantly associated with OS, and patients with high mGPS had shorter survival durations (HR = 1.98, 95% CI, 1.65-2.37, *P* \< .001, [Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 2A](#fig2-1559325820942065){ref-type="fig"}). Subgroup analysis was performed according to ethnicity, treatment, and sample size. The combined data indicated that mGPS remained a significant prognostic factor for OS irrespective of ethnicity ([Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 2B](#fig2-1559325820942065){ref-type="fig"}) or sample size ([Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 2D](#fig2-1559325820942065){ref-type="fig"}). In addition, a high mGPS was also associated with poor OS in patients receiving surgical resection, chemotherapy, and mixed treatment ([Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 2C](#fig2-1559325820942065){ref-type="fig"}).

###### 

Subgroup Analysis of the Studies Reporting the Association of mGPS and Prognosis in Pancreatic Cancer.

![](10.1177_1559325820942065-table2)

  Stratified analysis   Number of studies (cohorts)   Number of patients   Effects model   HR (95% CI)        *P*      Heterogeneity *I* ^2^ (%)   *P*
  --------------------- ----------------------------- -------------------- --------------- ------------------ -------- --------------------------- --------
  OS                                                                                                                                               
   Total                24                            4651                 Random          1.98 (1.65-2.37)   \<.001   68.1                        \<.001
  Ethnicity                                                                                                                                        
   Asian                20                            4027                 Random          2.11 (1.68-2.65)   \<.001   71.7                        \<.001
   Caucasian            4                             624                  Fixed           1.59 (1.35-1.89)   \<.001   0                           .812
  Treatment                                                                                                                                        
   Surgical resection   9                             1729                 Fixed           2.01 (1.71-2.38)   \<.001   42.1                        .087
   Chemotherapy         10                            993                  Random          2.06 (1.45-2.93)   \<.001   73.7                        \<.001
   Mixed                4                             1810                 Random          2.28 (1.48-3.52)   \<.001   79.0                        .003
   Chemoradiotherapy    1                             119                  --              1.03 (0.60-1.77)   .915     --                          --
  Sample size                                                                                                                                      
   \<175                14                            1283                 Random          2.01 (1.51-2.69)   \<.001   67.0                        \<.001
   ≥175                 10                            3368                 Random          1.98 (1.55-2.51)   \<.001   71.5                        \<.001
  PFS/DFS/CSS                                                                                                                                      
   Total                7                             1202                 Random          1.95 (1.36-2.80)   \<.001   74.8                        .001
  Ethnicity                                                                                                                                        
   Asian                5                             831                  Fixed           2.33 (1.84-2.94)   \<.001   38.1                        .167
   Caucasian            2                             371                  Fixed           1.14 (0.90-1.45)   .284     0                           .711
  Treatment                                                                                                                                        
   Surgical resection   3                             627                  Random          1.75 (1.01-3.05)   .048     84.4                        .002
   Chemotherapy         4                             575                  Random          2.26 (1.24-4.10)   .007     72.2                        .013
  Sample size                                                                                                                                      
   \<175                3                             248                  Random          2.32 (0.90-5.99)   .083     82.9                        .003
   ≥175                 4                             954                  Random          1.89 (1.27-2.83)   .002     71.7                        .014

Abbreviations: CI, confidence interval; CSS, cancer-specific survival; DFS, disease-free survival; HR, hazard ratio; mGPS, modified Glasgow prognostic score; OS, overall survival; PFS, progression-free survival; TNM, tumor--node--metastasis.

![Forest plots of the significant correlation of modified Glasgow prognostic score with overall survival in pancreatic cancer: (A) in total patients, (B) subgroup analysis stratified by ethnicity, (C) subgroup analysis stratified by treatment method, and (D) subgroup analysis stratified by sample size.](10.1177_1559325820942065-fig2){#fig2-1559325820942065}

Correlation Between mGPS and PFS/DFS/CSS {#section11-1559325820942065}
----------------------------------------

Seven cohorts with 1202 patients^[@bibr18-1559325820942065],[@bibr29-1559325820942065][@bibr30-1559325820942065]-[@bibr31-1559325820942065],[@bibr35-1559325820942065],[@bibr38-1559325820942065]^ provided data on the prognostic effect of mGPS in PFS/DFS/CSS. There was significant heterogeneity (*I* ^2^ = 74.8%, *P* = .001, [Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 3A](#fig3-1559325820942065){ref-type="fig"}); therefore, a random-effects model was selected. The pooled HR and 95% CI were HR = 1.95, 95% CI = 1.36-2.80, *P* \< .001 ([Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 3A](#fig3-1559325820942065){ref-type="fig"}), indicating that a higher mGPS was significantly correlated with poor PFS/DFS/CSS. Subgroup analysis was also carried out, stratified by ethnicity, treatment, and sample size. The results of the subgroup analysis showed that a high mGPS was correlated with inferior PFS/DFS/CSS in Asian patients (HR = 2.33, 95% CI, 1.84-2.94, *P* \< .001, [Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 3B](#fig3-1559325820942065){ref-type="fig"}), in patients receiving surgical resection (HR = 1.75, 95% CI, 1.01-3.05, *P* = .048) and receiving chemotherapy (HR = 2.26, 95% CI, 1.24-4.10, *P* = .007; [Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 3C](#fig3-1559325820942065){ref-type="fig"}) and in studies with a sample size ≥175 (HR = 1.89, 95% CI, 1.27-2.83, *P* = .002, [Table 2](#table2-1559325820942065){ref-type="table"}; [Figure 3D](#fig3-1559325820942065){ref-type="fig"}).

![Forest plots of the significant correlation of mGPS with PFS/DFS/CSS in pancreatic cancer: (A) in total patients, (B) subgroup analysis stratified by ethnicity, (C) subgroup analysis stratified by treatment method, and (D) subgroup analysis stratified by sample size. CSS indicates cancer-specific survival; DFS, disease-free survival; mGPS, modified Glasgow prognostic score; PFS, progression-free survival.](10.1177_1559325820942065-fig3){#fig3-1559325820942065}

Sensitivity Analysis {#section12-1559325820942065}
--------------------

To assess the stability of the pooled results, sensitivity analysis was performed by sequentially omitting individual study. The pooled HRs for OS ([Figure 4A](#fig4-1559325820942065){ref-type="fig"}) and PFS/DFS/CSS ([Figure 4B](#fig4-1559325820942065){ref-type="fig"}) were not substantially changed, indicating the reliability of our results.

![Sensitivity analysis of included studies for association between mGPS and (A) OS and (B) PFS/DFS/CSS in pancreatic cancer. CSS indicates cancer-specific survival; DFS, disease-free survival; mGPS, modified Glasgow prognostic score; OS, overall survival; PFS, progression-free survival.](10.1177_1559325820942065-fig4){#fig4-1559325820942065}

Publication Bias {#section13-1559325820942065}
----------------

Begg funnel plot was used to evaluate the potential publication bias for OS and PFS/DFS/CSS. As shown in [Figure 5](#fig5-1559325820942065){ref-type="fig"}, there was no significant publication bias for OS (Begg test, *P* = .385) or for PFS/DFS/CSS (Begg test, *P* = .085).

![Publication bias tested by Begg funnel plot. (A) Begg test for OS, *P* = .385; (B) Begg test for PFS/DFS/CSS, *P* = .085. CSS indicates cancer-specific survival; DFS, disease-free survival; OS, overall survival; PFS, progression-free survival.](10.1177_1559325820942065-fig5){#fig5-1559325820942065}

Discussion {#section14-1559325820942065}
==========

The prognostic role of mGPS for patients with pancreatic cancer has been explored in many previous studies,^[@bibr15-1559325820942065][@bibr16-1559325820942065][@bibr17-1559325820942065][@bibr18-1559325820942065][@bibr19-1559325820942065][@bibr20-1559325820942065][@bibr21-1559325820942065][@bibr22-1559325820942065][@bibr23-1559325820942065][@bibr24-1559325820942065][@bibr25-1559325820942065][@bibr26-1559325820942065][@bibr27-1559325820942065][@bibr28-1559325820942065][@bibr29-1559325820942065][@bibr30-1559325820942065][@bibr31-1559325820942065][@bibr32-1559325820942065][@bibr33-1559325820942065][@bibr34-1559325820942065][@bibr35-1559325820942065][@bibr36-1559325820942065][@bibr37-1559325820942065][@bibr38-1559325820942065][@bibr39-1559325820942065]-[@bibr40-1559325820942065]^ with the conflicting results presented. Therefore, we aggregated data from 26 eligible studies comprising 5198 patients. Our meta-analysis showed that a high mGPS (score 1-2) was associated with worse OS and PFS/DFS/CSS in pancreatic cancer. To further investigate the association between mGPS and survival in various patient groups, subgroup analysis was conducted, and the data showed that mGPS remained a significant prognostic factor for OS, irrespective of ethnicity or sample size. In addition, a high mGPS was correlated with inferior PFS/DFS/CSS in Asian patients, in patients undergoing surgical resection and receiving chemotherapy. Taken together, our meta-analysis indicated that an elevated mGPS was correlated with poor survival outcomes in patients with pancreatic cancer. Moreover, the reliability of the results was confirmed by quality assessments, sensitivity analysis, and publication bias tests. To the best of our knowledge, the current study was the first meta-analysis to explore the prognostic role of mGPS in pancreatic cancer.

The survival of patients with cancer is associated with nutritional status, and approximately one-third of cancer-related deaths are attributed to malnutrition rather than cancer.^[@bibr45-1559325820942065],[@bibr46-1559325820942065]^ In recent years, much attention has been paid to the prognostic effect of combinational nutritional parameters, such as mGPS, which is derived from Alb and CRP in peripheral blood. Briefly, patients with lower Alb and high CRP levels scored a high mGPS. The mechanisms of association between mGPS and poor survival could be explained by the following aspects. First, Alb is a major protein in the blood. Serum Alb is an objective indicator of nutritional status, and hypoalbuminemia is reflective of malnutrition in patients with cancer. Albumin is also regarded as an acute-phase protein and is downregulated in inflammation.^[@bibr47-1559325820942065]^ Current evidence has shown that serum Alb is associated with anticancer activity, for example, its antioxidant effect.^[@bibr48-1559325820942065]^ When hepatocytes generate Alb normally in patients with cancer, they are more resistant to disease and tumor growth.^[@bibr49-1559325820942065]^ Therefore, reduced serum Alb level is a predictor of poor prognosis in various cancers, including urothelial carcinoma,^[@bibr50-1559325820942065]^ colorectal cancer,^[@bibr51-1559325820942065]^ and non-small cell lung cancer.^[@bibr52-1559325820942065]^ Second, CRP is a common acute-phase serum protein that is synthesized by liver cells.^[@bibr53-1559325820942065]^ Cancer cells secrete inflammatory cytokines, which strongly stimulate CRP production in liver.^[@bibr54-1559325820942065]^ Previous studies indicated that high levels of serum CRP were significantly associated with poor OS in patients with cancer.^[@bibr55-1559325820942065][@bibr56-1559325820942065]-[@bibr57-1559325820942065]^ The mGPS enables better appreciation of systemic inflammation or malnutrition through changes in Alb and CRP levels. The high mGPS is indicative of low Alb and high CRP, which usually suggests malnutrition and severe systemic inflammation in patients with pancreatic cancer. Thus, mGPS, as a combinational index of Alb and CRP, is efficient in prognostication of survival in patients with cancer. Patients with high mGPS usually have poor survival outcomes.

A variety of meta-analyses have also investigated the prognostic value of mGPS in solid tumors.^[@bibr58-1559325820942065][@bibr59-1559325820942065][@bibr60-1559325820942065]-[@bibr61-1559325820942065]^ A meta-analysis incorporating 12 studies with 2391 patients showed that higher mGPS significantly correlated with worse OS, CSS, recurrence-free survival, and PFS in patients with RCC.^[@bibr60-1559325820942065]^ Subgroup analyses also confirmed the overall results. Moreover, another meta-analysis demonstrated that elevated mGPS predicted poorer OS in patients with lung cancer.^[@bibr58-1559325820942065]^ A recent meta-analysis by Zhang et al^[@bibr62-1559325820942065]^ showed that OS was worse in patients with an mGPS of 1 and 2 compared with those with a score of 0 in patients with gastric cancer. In the current meta-analysis, our findings on pancreatic cancer were in accordance with the results of other types of cancer. In addition, the subgroup analysis also confirmed the consistent prognostic efficiency of mGPS in different subpopulations. In the present meta-analysis, only English studies were included to guarantee the availability of all eligible publications to investigators. English publications are available to most investigators around the world, and the data of included studies can also be extracted and examined. Notably, publications in non-English language were not selected, which may contribute to heterogeneity in this meta-analysis.

This meta-analysis has several limitations. First, all of the included studies were retrospective, which may have introduced selection bias in this meta-analysis. Second, the heterogeneity among the included studies was significant. Although we adopted a random-effects model to calculate the pooled data. The inherent heterogeneity among retrospective studies may still exist. Third, the relationship between mGPS and clinicopathological features in pancreatic cancer could not be analyzed due to insufficient information in recruited studies. Fourth, most eligible studies are from Asian countries, especially Japan, which decreases the study's significance to the global community. The results may be applicable to Asian patients with pancreatic cancer. Therefore, further large-scale prospective studies are necessary to validate our results.

Conclusions {#section15-1559325820942065}
===========

In summary, our meta-analysis demonstrated that high mGPS correlated with worse OS, PFS, DFS, and CSS in patients with pancreatic cancer. Therefore, mGPS could be employed as an effective prognostic factor for pancreatic cancer in clinical practice.
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